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A clinical profile and factors associated with severity of the 
disease among Polish patients hospitalized due to COVID-19 
— an observational study
Abstract
Introduction: The coronavirus disease 2019 (COVID-19) is one of the greatest clinical challenges of the last decades. Clinical fac-
tors associated with severity of the disease remain unclear. The aim of the study was to characterize Polish patients hospitalized 
due to COVID-19 and to evaluate potential prognostic factors of severe course of the disease.
Material and methods: An observational study was conducted from March to July 2020 in the Pulmonology and Allergology 
Department of the University Hospital in Kraków, Poland. Consecutive patients with confirmed SARS-CoV-2 (Severe Acute Re-
spiratory Syndrome Coronavirus 2) infection were enrolled, and data about past medical history, signs and symptoms, laboratory 
results, imaging studies results, in-hospital management and outcomes was prospectively gathered.
Results: The study sample comprised 100 patients at the mean age of 59.2 (SD 16.1) years among whom 63 (63.0%) were 
male. Among them 10 (10.0%) died, 47 (47%) presented respiratory failure, 15 (15.0%) were transferred to the intensive care 
unit, 17 (17.0%) developed acute kidney injury, 7 (7.0%) had sepsis and 10 (10.0%) were diagnosed with pulmonary embolism. 
Multivariable analysis revealed age (OR 1.1; 95% CI 1.01–1.15), body mass index (BMI; OR 1.24; 95% CI 1.01–1.53), modified 
early warning score (MEWS; OR 3.95; 95% CI 1.48–12), the highest d-dimer value (OR 1.73; 95% CI 1.03–2.9) and lactate dehy-
drogenase (LDH; OR 1.16; 95% CI 1.03–1.3) to be associated with severe course of COVID-19.
Conclusion: This observational study showed that almost half of hospitalized patients with COVID-19 developed respiratory 
failure in the course of the disease. Increasing age, BMI, MEWS, d-dimer value and LDH concentration were associated with the 
severity of COVID-19.
Key words: clinical characteristics, coronavirus disease 2019, respiratory failure, risk factors,  SARS-CoV-2
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Introduction
Clinical presentation of COVID-19 is highly 
variable and involves multiple organs, however, 
the respiratory system seems to be predominant-
ly affected. There are several reports describing 
an increased incidence of injuries to the heart, 
kidneys, muscles, gastrointestinal tract and the 
nervous system among COVID-19 patients [1–3]. 
Another significant factor influencing outcomes 
of persons infected with SARS-CoV-2 is an in-
creased incidence of thromboembolic complica-
tions which is secondary to severe disturbances in 
coagulation and fibrinolysis as well as endothelial 
damage, sometimes referred to as COVID-19-as-
sociated coagulopathy [4, 5]. It is estimated that 
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SARS-CoV-2 infection remains mildly symp-
tomatic in about 80% of patients. However, ap-
proximately 15% of cases are severe, warranting 
hospitalization and the remaining 5% of patients 
are critically ill and require management in the 
intensive care unit (ICU) [6]. At the time of the 
study, only systemic glucocorticoids were recog-
nized to reduce mortality in several randomized 
controlled trials [7]. 
The objective of this study was to charac-
terize the first COVID-19 patients treated in the 
Pulmonology and Allergology Department of the 
University Hospital in Kraków, Poland in terms 
of patients’ clinical, laboratory, diagnostic out-
comes and factors associated with the severity 
of the disease. 
Material and methods
Study design
This is an observational study conducted 
from March to July 2020 in the Pulmonology 
and Allergology Department, University Hospi-
tal in Kraków, Poland. The study was approved 
by the Ethics Committee of Jagiellonian Uni-
versity Medical College, Kraków, Poland (KBET 
1072.6120.145.2020), and written informed con-
sent was obtained from all participants.
Study sample and data collection
We enrolled all consecutive patients with 
SARS-CoV-2 infection confirmed using reverse 
transcription polymerase chain reaction, admitted 
to the Pulmonology and Allergology Department. 
We collected basic demographic (age, sex) and 
detailed clinical information about the patients 
(symptoms, comorbidities, medications, smoking 
status) based on the interviews and comprehen-
sive analysis of medical records. In each patient, 
modified early warning score (MEWS) was cal-
culated on  admission. We recorded laboratory 
results on the day of admission, on the 2nd to 
4th day of hospitalization and the 6th to 8th day 
of hospitalization as well as results of imaging 
studies (chest X-ray and computed tomography 
of the chest). 
Outcomes
The patients were observed during the en-
tire hospitalization in the University Hospital 
for the occurrence of the following outcomes: 
death, myocardial injury, myocardial infarction 
(both defined according to the Fourth Universal 
Definition of Myocardial Infarction [8]), stroke 
(defined as a new focal neurological deficit with 
signs and symptoms lasting more than 24 hours), 
acute kidney injury (AKI, diagnosed according to 
the Kidney Disease Improving Global Outcomes 
definition) [9], sepsis, septic shock (both defined 
according to the 2016 Surviving Sepsis Campaign 
International Guidelines for Management of Sep-
sis and Septic Shock) [10], pulmonary embolism 
(diagnosed with computed tomography pulmo-
nary angiogram) as well as transfer to the ICU 
and a need for mechanical ventilation. 
Statistical analysis
Categorical variables were presented as num-
bers (percentages), whereas continuous variables 
were reported as medians (interquartile range) or 
means (standard deviation) depending on variable 
distribution. Associations of quantitative data 
were analyzed with Student t test and with the 
nonparametric Mann–Whitney U test. To assess 
the association between selected factors and a se-
vere course of the disease (defined as necessity 
to administer oxygen therapy), a multivariable 
logistic regression model was created. The vari-
ables for the model (age, sex, the highest d-dimer 
value during hospitalization, MEWS on admis-
sion, baseline LDH concentration) were selected 
based on the available evidence. The model was 
validated using the Hosmer-Lemeshow test. This 
was a complete-case analysis. After application 
of Bonferroni correction due to multiple testing, 
a p-value < 0.00062 was considered statistically 
significant. Statistical analysis was performed 
with STATISTICA software (Statsoft, Tulsa, USA).
Results
Baseline characteristics
The study group consisted of 100 patients 
with the mean age of 59.2 (SD 16.1) years among 
whom 63 (63.0%) were male. The most common 
comorbidities were hypertension (49.0%), obesity 
(31.0%) and dyslipidemia (19.0%). Twenty-seven 
patients (27.0%) had history of smoking. The most 
commonly used medications were b-blockers 
(35.0%), diuretics (24.0%), ACE inhibitors and 
statins (both 19.0%). Detailed demographic and 
clinical characteristics are presented in Table 1. 
Signs and symptoms
The most common symptoms described by 
the patients on admission were fever (73.0%), 
cough (67.0%) and dyspnea (44.0%). Additionally, 
diarrhea and dysgeusia or dysosmia were reported 
by 29 (29.0%) and 15 (15.0%) patients, respective-
ly. The median time from the onset of symptoms 
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Table 1. Baseline characteristics
Characteristic Total (n = 100)
Demographic
Age [years], mean (SD) 59.2 (16.1)
Sex, male 63 (63.0%)
Smoking 27 (27.0%)
Symptoms
Time from first symptoms to positive swab [days] 5.0 (1.0–7.0)
Time from first symptoms to admission [days] 7.0 (3.0–9.0)
Fever prior to admission 73 (73.0%)
Sore throat 16 (16.0%)
Dyspnea 44 (44.0%)
Pleuritic chest pain 13 (13.0%)






Dysgeusia or dysosmia 15 (15.0%)
Measurements & vital signs on admission
Resting baseline SpO2 on admission [%] 95.0 (93.0–96.0)
BMI [kg/m2] 27.7 (25.2–30.8)
Systolic blood pressure on admission [mm Hg] 130.0 (123.5–145.5)
Diastolic blood pressure on admission [mm Hg] 82.5 (77.0–90.0)
Heart rate on admission [beats/minute] 86.5 (77.0–95.5)
Respiratory rate on admission [breaths/minute] 16.0 (14.0–20.0)
Fever on admission 3 (3.0%)
MEWS on admission 1.0 (0.0–2.0)
Comorbidities
Hypertension 49 (49.0%)
Atrial fibrillation 9 (9.0%)
Chronic heart failure 11 (11.0%)
Coronary artery disease 15 (15.0%)
History of myocardial infarction 9 (9.0%)
History of stroke 3 (3.0%)




Diabetes mellitus 16 (16.0%)
Obesity 31 (31.0%)
Chronic kidney disease 6 (6.0%)
Asthma 10 (10.0%)
COPD 7 (7.0%)
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to admission to the hospital was 7.0 (IQR 3.0–9.0) 
days. Hypotension (defined as systolic blood 
pressure < 90 mm Hg), tachycardia (defined as 
heart rate > 100/min) and tachypnea (defined 
as respiratory rate > 20 breaths/min) were ob-
served on admission in 0 (0.0%), 11 (11.0%) and 
23 (23.0%) patients, respectively. The median 
MEWS on admission was 1.0 (IQR 0.0–2.0) point.
Laboratory results
Complete blood count most often revealed 
lymphopenia (35/100, 35.0%), while thrombo-
cytopenia was present in 17 patients (17.0%). 
Coagulation tests commonly showed an increased 
concentration of fibrinogen (50/59, 84.7%), d-di-
mer (53/84, 63.1%) and prolonged APTT (16/89, 
18.3%). Renal function, reflected by estimated 
glomerular filtration rate (eGFR), was normal in 
the majority of patients (82/100, 82.0%). Serum 
concentrations of liver enzymes were commonly 
elevated, i.e. alanine aminotransferase (ALT; 
45/100, 45.0%), aspartate aminotransferase (AST; 
48/91, 52.7%) and gamma-glutamyl transpep-
tidase (GGTP; 53/74, 71.6%). The majority of 
patients had elevated level of lactate dehydro-
genase (LDH; 78/96, 81.3%). Among markers of 
inflammation we observed elevation of C-reactive 
protein (CRP), procalcitonin (PCT) and interleu-
kin 6 (IL-6) in 79/100 (79.0%), 29/96 (30.2%) and 
39/71 (54.9%) patients, respectively. Medians 
with IQR as well as proportions of patients with 
abnormalities in laboratory results are summa-
rized in Table 2. 
Imaging studies
Chest X-ray was performed in 99 patients 
(99.0%). There were no discernible pathological 
findings in 22 cases (22.0%). Interstitial infiltrates 
and consolidations were described in 22 (22.0%) 
and 19 patients (19.0%), respectively. The coexis-
tence of interstitial infiltrates and consolidations 
was reported in 35 patients (35.0%). One subject 
had extensive neoplastic changes, which made 
chest X-ray analysis impossible.
Computed tomography was performed in 
45 patients (45.0%) — computed tomography 
pulmonary angiogram in 43 cases and high-res-
olution computed tomography in 2 cases. Among 
patients with available CT results, ground-glass 
opacities were described in 38 cases (84.4%), 
consolidations were found in 29 patients (64.4%), 
and pleural fluid was detected in 11 individuals 
(24.4%).
Management
Low-molecular-weight heparin (LMWH) was 
administered in 90 patients (90.0%) with the 
maximal administered dose being prophylactic 
in 39 patients (39.0%), intermediate in 28 sub-
jects (28.0%) and therapeutic in 23 patients 
(23.0%). The majority of patients (69/100, 69.0%) 
received antibiotics while chloroquine and ritona-
vir/lopinavir were administered in 36 (36.0%) 
and 2 (2.0%) individuals, respectively. Oxygen 
therapy was used in 47 patients (47.0%) during 
hospitalization, with the median maximal FiO2 ac-
counting for 50.0% (IQR 28.0–90.0).
Active neoplastic disease 6 (6.0%)
History of DVT/PE 7 (7.0%)
Medications
Acetylsalicylic acid 14 (14.0%)
Oral anticoagulants 3 (3.0%)








Data is presented as n [%] for categorical variables and median (interquartile range) unless otherwise specified. ACE-I — angiotensin converting enzyme inhibitors; ARB 
— angiotensin receptor blockers; BMI — body mass index; COPD — chronic obstructive pulmonary disease; DVT/PE — deep vein thrombosis/pulmonary embolism; 
MEWS — modified early warning score; SD — standard deviation
Table 1. cont. Baseline characteristics
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Outcomes
Among 100 enrolled patients, 10 (10.0%) 
died, 47 (47.0%) developed respiratory failure, 
15 (15.0%) were transferred to the ICU, 17 (17.0%) 
presented AKI, 7 (7.0%) had sepsis, and 10 (10.0%) 
were diagnosed with pulmonary embolism. The 
median time of hospitalization was 19.5 days (IQR 
14.0-31.5) while median time of ICU stay account-
ed for 12.0 (IQR 6.0–19.0) days. The majority of 
patients (52/100, 52.0%) were discharged with 
positive result of nasal swab for SARS-CoV-2 and 
were isolated at home. The median time to viral 
clearance among 81 subjects with available nega-
tive result was 31.0 (IQR 20.0–37.0) days. Details 
concerning management and outcomes are sum-
marized in Table 3.
Factors associated with severity of the 
disease — the univariable analysis
Patients with severe COVID-19 had a higher 
MEWS on admission and more often presented 
with dyspnea. Moreover, in terms of laboratory 
results, COVID-19 patients requiring oxygen ther-
apy were characterized by a higher white blood 
cell and neutrophil count, lower lymphocyte 
count, higher d-dimer levels as well as higher 
concentrations of inflammatory markers, liver 
damage enzymes, LDH, myoglobin, NT-proBNP 
and troponin. Treatment differences between 
these groups included more frequent adminis-
tration of antibiotics and chloroquine. Detailed 
information about between-group differences are 
summarized in Table 4. A complete comparison 
Table 2. Baseline laboratory tests results 
Parameter Value; median (IQR) Patients with abnormal values; n(%)
White blood count [×103/mm3] 5.95 (4.56–7.59) Leukopenia: 19/100 (19.0%)
Leukocytosis: 11/100 (11.0%)
Neutrophils, count [×103/mm3] 3.96 (2.69–5.69) Neutropenia: 4/100 (4.0%)
Lymphocytes, count [×103/mm3] 1.12 (0.88–1.50) Lymphopenia: 35/100 (35.0%)
Hemoglobin [g/dl] 13.8 (12.7–14.8) Anaemia: 18/100 (18.0%)
Platelets [×103/mm3] 197.5 (159.5–257.0) Thrombocytopenia: 17/100 (17.0%)
D-dimer on admission [mg/L] 0.84 (0.47–1.42) Elevation: 53/84 (63.1%)
Highest d-dimer [mg/L] 1.20 (0.74–2.44) Elevation: 67/81 (82.7%)
Fibrinogen [g/L] 4.7 (3.7–5.9) Elevation: 50/59 (84.7%)
APTT [s] 31.9 (28.7–35.1) Prolongation: 16/89 (18.3%)
INR 0.95 (0.90–1.02) Elevation: 4/98 (4.1%)
eGFR [mL/min/1.73 m2] 87.0 (66.9–104.7) Decreased: 18/100 (18.0%)
Urea [mmol/L] 5.3 (3.8–6.9) Elevation: 17/99 (17.2%)
Glucose [mmol/L] 5.7 (5.2–7.0) Elevation: 48/93 (51.8%)
ALT [U/L] 31.5 (20.5–61.0) Elevation: 45/100 (45.0%)
AST [U/L] 37.0 (27.0–56.0) Elevation: 48/91 (52.7%)
Bilirubin [µmol/L] 7.3 (5.7–9.0) Elevation: 0/85 (0.0%)
GGTP [U/L] 49.0 (26.0–107.0) Elevation: 53/74 (71.6%)
Myoglobin [µg/L] 72.2 (42.9–118.2) Elevation: 21/70 (30.0%)
Creatine kinase [U/L] 114.0 (64.0–189.0) Elevation: 22/90 (24.4%)
Ferritin [µg/L] 400.0 (223.0–949.0) Elevation: 35/71 (49.3%)
Lactate dehydrogenase [U/L] 270.0 (224.5–361.0) Elevation: 78/96 (81.3%)
NT-proBNP [pg/mL] 186.0 (69.0–1061.0) Elevation: 38/71 (53.5%)
Troponin I [ng/L] 5.3 (2.5–14.4) Elevation: 7/80 (8.8%)
C-reactive protein [mg/L] 37.0 (9.8–91.0) Elevation: 79/100 (79.0%)
Procalcitonin [ng/mL] 0.04 (0.02–0.11) Elevation: 29/96 (30.2%)
Interleukin-6 [pg/mL] 19.1 (1.5–52.6) Elevation: 39/71 (54.9%)
ALT — alanine transferase; APTT — activated partial thromboplastin time; AST — aspartate aminotransferase; eGFR — estimated glomerular filtration rate; GGTP — 
gamma-glutamyl transpeptidase; INR — international normalized ratio; NT-proBNP — N-terminal pro brain natriuretic peptide
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of demographic, clinical, laboratory data can be 
found in Supplementary Tables 1–3. 
Factors associated with severity of the 
disease — the multivariable analysis
Multivariable analysis revealed that severe 
course of COVID-19 is associated with increased 
age (OR 1.10; 95% CI 1.01–1.15), BMI (OR 1.24; 
95% CI 1.01–1.53), MEWS on admission (OR 3.95; 
95% CI 1.48–12.0), the highest d-dimer value 
during hospitalization (OR 1.73; 95% CI 1.03-
2.90) and baseline LDH concentration (OR 1.16; 
95% CI 1.03–1.30). The validation of the model 
was performed using the Hosmer and Lemeshow 
goodness of fit test (X2 = 18.12, p = 0.02). Logistic 
regression results are summarized in Figure 1 and 
Supplementary Table 4.
Discussion
To our knowledge, this is one of the first 
manuscripts describing a prospective cohort of 
Polish COVID-19 patients, and we believe that it 
may be useful for local clinicians involved in the 
care of patients with SARS-CoV-2. 
The presented study cohort consisted pre-
dominantly of males and the mean age amounted 
to 59.2 years, which confirms the results of several 
previous studies reporting higher representation 
of males in hospitalized patients [1, 2, 11, 12]. El-
derly persons with COVID-19 are characterized by 
a high case fatality ratio and symptomatic infec-
tion rate [13, 14]. In a Chinese modeling study, the 
rate of hospitalization due to COVID-19 increased 
with age, ranging from 1% for patients aged 
20 to 29 years, through 8% for those aged 50 to 
59 years, up to 18% for individuals older than 
80 years [15]. Underlying medical comorbidities 
are considered important risk factors for severe 
COVID-19 course and mortality. The most com-
mon comorbidities in the presented cohort were 
hypertension (49%), obesity (31%) and dyslipid-
emia (19%), which is comparable to several large 
studies from the United States and China. Upon 
initial presentation, COVID-19 symptoms are 
typically consistent with pneumonia [3, 16–18]. 
The majority of patients in this case series were 
hospitalized due to a cluster of flu-like symptoms, 
i.e. fever (73.0%), cough (67.0%) and dyspnea 
(44.0%). Additionally, we observed a significant 
representation of gastrointestinal symptoms as 
well as other typical COVID-19 symptoms, i.e. 
loss of smell or taste, which was present in 15% 
of cases. In a report published by the Centers for 
Disease Control and Prevention, the described 
symptoms of COVID-19 included: cough (50%), 
fever > 38°C (43%), myalgia (36%), headache 
(34%), dyspnea (29%), sore throat (20%), diarrhea 
(19%), nausea/vomiting (12%), loss of smell or 
taste, abdominal pain, and rhinorrhea in fewer 
than 10 percent each [19].  
A number of observational studies involving 
COVID-19 patients revealed a unique pattern of 
laboratory changes, encompassing hemostatic 
derangements and pronounced hyperinflamma-
tory state. First, there are numerous reports about 
significant coagulation abnormalities, including 
increased concentrations of fibrinogen and d-di-
mer as well as relatively common prolongation 
Table 3. Treatment and outcomes
Treatment Number of patients; n [%]
Treatment
Prophylactic LMWH 39 (39.0%)
Intermediate dose LMWH 28 (28.0%)
Therapeutic dose LMWH 23 (23.0%)




Oxygen therapy on admission 33 (33.0%)
FiO2 on admission 36.0 (28.0–40.0)
Oxygen therapy anytime during 
hospitalization
47 (47.0%)
Highest FiO2 during hospitalisation 5.0 (28.0–90.0%)
Outcomes
Mortality 10 (10.0%)
Mechanical ventilation 8 (8.0%)
Transfer to the ICU 15 (15.0%)
Pulmonary embolism 10 (10.0%)
Myocardial injury 7 (7.0%)
Myocardial infarction 1 (1.0%)
Stroke 0 (0.0%)
Acute kidney injury 17 (17.0%)
Sepsis 7 (7.0%)
Septic shock 6 (6.0%)
Length of hospitalisation [days] 19.5 (14.0–31.5)
Length of ICU stay [days] 12.0 (6.0–19.0)
Positive swab at discharge 52 (52.0%)
Time to negative swab  [days] (n 
= 81)
31.0 (20.0–37.0)
ICU — intensive care unit; LMWH — low molecular weight heparin
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of coagulation times. Coagulation tests in the 
presented cohort showed an increased concen-
tration of fibrinogen and d-dimer in the majority 
of patients and prolonged APTT in nearly 20% of 
cases. Another frequently described laboratory 
anomaly is thrombocytopenia, which was present 
in 17% of the study group and in 5.0 to 41.7% 
of patients in the previous reports. According 
to the studies, utilizing global coagulation tests 
(rotational thromboelastometry, thrombography) 
COVID-19-associated coagulopathy represents 
severe hypercoagulability, which most probably 
is consistent neither with disseminated intravas-
cular coagulation nor consumptive coagulopathy. 
Importantly, both abnormalities in coagulation 
tests and thrombocytopenia seem to be associated 
with disease severity and mortality [20]. Second, 
the majority of patients in the current study had 
laboratory findings suggestive of an exuberant 
inflammatory response reflected by markedly 
elevated concentrations of CRP, PCT, ferritin and 
IL-6. These observations are in line with some 
previous reports suggesting significant role of 
hyperinflammatory state with cytokine release 
syndrome in the pathogenesis of COVID-19 and 
its association with critical and fatal illness 
[1, 21]. Finally, recent data suggests that liver 
injury is quite common among patients with 
COVID-19 [22]. This was also observed in the 
current study cohort – serum concentrations of 
liver enzymes (ALT, AST, GGTP) and cellular 
damage markers (LDH) were frequently elevated. 
Importantly, according to the  recent meta-anal-
ysis, liver injury seems to be more prevalent in 
severe cases of COVID-19 [23].
Radiological findings may vary depending on 
disease stage, patients age, immunity status and 
comorbidities [24] . Normal chest radiographs 
or CT are found in only 18% of patients with 
mild disease and this proportion drops to 3% 
in severely ill patients. Typical CT findings in 
COVID-19 include bilateral, multilobar ground 
glass opacities with a peripheral or posterior 
distribution, mainly in the lower lobes, while 
consolidation at the initial imaging are less com-
mon (more frequent in elderly people). Moreover, 
pleural effusion is an uncommon but a possible 
finding, sometimes accompanying the disease 
progression [25]. In the presented study, chest 
radiographs were performed in nearly all patients 
upon admission to the hospital and similarly to 
data presented above,  were normal in 23.9% of 
cases, while the remaining patients presented 
interstitial infiltrates, consolidations or both. 
Important strength of this study is high availabil-
ity of CT scans which were performed in almost 
half of the studied patients and most commonly 
showed ground glass opacities followed by con-
solidations and presence of fluid in the pleural 
space.
The frequency of reported complications in 
COVID-19 is strongly dependent on the studied 
population and disease severity. The most com-
monly observed organ involvement in patients 
with severe COVID-19 is lung injury manifested 
by acute respiratory failure. In this study, almost 
half of the studied cohort developed respiratory 
insufficiency, and 15% of patients were trans-
ferred to the ICU due to severe respiratory failure 
among whom more than a half required endotra-
Figure 1. Summary of multivariable regression results. Dots and whiskers represent odds ratios with 95% confidence intervals. BMI — body mass 
index; LDH — lactate dehydrogenase; MEWS — modified early warning score; OR — odds ratio
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Table 4. Comparison of selected variables between patients wit severe and non-severe COVID-19
Characteristic Severe cases (n = 47) Non–severe cases (n = 53) P–value
Demographic
Age [years], mean (SD) 62.3 (15.9) 56.5 (15.8) 0.07
Sex, male 30 (63.8%) 33 (62.3%) 0.87
Symptoms
Dyspnea 32 (68.1%) 12 (22.6%) < 0.0001
Measurements and vital signs on admission
BMI [kg/m2] 28.4 (26.1–32.1) 26.8 (24.9–28.6) 0.009
Heart rate on admission 90.0 (80.0–100.0) 82.0 (71.0–91.0) 0.007
Respiratory rate on admission 20.0 (17.0–22.0) 15.0 (14.0–16.0) < 0.0001
MEWS on admission 2.0 (1.0–2.0) 0.0 (0.0–1.0) < 0.0001
Comorbidities
Hypertension 29 (61.7%) 20 (38.5%) 0.02
Chronic heart failure 10 (21.3%) 1 (1.9%) 0.003
Laboratory results
White blood count [×103/mm3] 6.86 (5.70–9.83) 5.20 (3.87–6.58) < 0.0001
Neutrophils, count [×103/uL] 5.34 (3.92–8.15) 3.02 (2.03–4.01) < 0.0001
Lymphocytes, count [×103/uL] 1.00 (0.64–1.20) 1.38 (1.09–1.65) < 0.0001
D-dimer on admission [mg/L] 1.10 (0.74–2.08) 0.54 (0.35–1.07) < 0.0001
Highest d-dimer [mg/L] 2.20 (0.96–5.15) 0.91 (0.55–1.43) < 0.0001
APTT [s] 33.9 (30.2–38.2) 30.8 (27.8–33.1) 0.02
AST [U/L] 46.0 (35.0–68.0) 31 (24.0–41.5) 0.0003
GGTP [U/L] 72.5 (31.0–174.0) 40.0 (23.0–59.0) 0.003
Myoglobin [µg/L] 115.5 (66.4–175.5) 57.9 (38.6–77.9) < 0.0001
Ferritin [µg/L] 681.0 (379.0–1280.0) 308.0 (145.0–529.0) 0.0004
Lactate dehydrogenase [U/L] 354.0 (284.0–456.0) 232.0 (201.0–275.0) < 0.0001
NT-proBNP [pg/mL] 482.5 (134.0–2084.0) 93.0 (35.0–321.0) < 0.0001
Troponin I [ng/L] 12.7 (4.3–29.4) 3.7 (2.5–7.8) 0.0002
C-reactive protein [mg/L] 85.5 (34.5–170.0) 12.1 (2.3–48.2) < 0.0001
Procalcitonin [ng/mL] 0.10 (0.04–0.20) 0.02 (0.02–0.04) < 0.0001
Interleukin-6 [pg/mL] 29.3 (19.1–78.0) 1.5 (1.5–21.2) < 0.0001
Treatment
Antibiotics 45 (95.7%) 24 (45.3%) < 0.0001
Chloroquine 25 (53.2%) 11 (20.8%) < 0.0001
Outcomes
Pulmonary embolism 8 (17.0%) 2 (3.8%) 0.04
Acute kidney injury 13 (27.7%) 4 (7.6%) 0.014
Positive swab at discharge 19 (42.2%) 33 (62.3%) 0.047
Data is presented as n [%] for categorical variables and median (interquartile range) unless otherwise specified. ALT — alanine transferase; AST — aspartate ami-
notransferase; BMI — body mass index; GGTP — gamma-glutamyl transpeptidase; MEWS —  Modified Early Warning Score; NT-proBNP — N-terminal pro brain 
natriuretic peptide; SD — standard deviation.  The p < 0.00062 is considered significant
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cheal intubation and mechanical ventilation. In 
the previous studies from the USA, 12–24% of 
hospitalized patients required mechanical ven-
tilation [3, 17]. In a nationwide cross-sectional 
study performed in China including approxi-
mately 44,500 cases, one in twenty patients was 
categorized as critically ill (i.e. with respiratory 
failure, shock, or multiorgan dysfunction) [6]. 
Importantly, thromboembolic complications are 
markers of severe COVID-19 and are associated 
with multiorgan failure and increased mortality 
[26]. The evidence to date supports the concept 
that the thrombotic manifestations of severe 
COVID-19 are due to the ability of SARS-CoV-2 to 
invade endothelial cells via ACE-2 (angioten-
sin-converting enzyme 2). Ten percent of patients 
in our cohort were diagnosed with pulmonary em-
bolism despite the fact that LMWH was adminis-
tered in 90% of the analyzed cases. Depending on 
the population and  type of study (retrospective 
vs prospective with active screening for venous 
thromboembolism), the incidence of thromboem-
bolic complications ranges from 3.9% to 79.4% 
in the ICU patients and from 1.3 to 14.7% among 
non-critically ill patients [27]. Kidney involve-
ment in COVID-19 is frequent, with clinical pre-
sentation ranging from mild proteinuria to AKI 
necessitating renal replacement therapy [28]. In 
our study, a baseline renal function was normal 
in the majority of patients (82%). In the course 
of the hospitalization, 7% of our patients have 
developed AKI, which corroborates the results of 
the recently published meta-analysis estimating 
the incidence of AKI among hospitalized patients 
at the level of 8.9% [29]. It is important to note 
that a substantial proportion of AKI could have 
been missed due to limited sensitivity of serum 
creatinine. The role of secondary infections in 
COVID-19 may be overestimated, although data is 
limited [30, 31]. In a review, the rate of bacterial 
or fungal coinfections was only 8%, whereas in 
our study, 7% of hospitalized patients developed 
sepsis or septic shock [30].
Finding an effective treatment for COVID-19 was 
a long and tortuous road filled with many hopes 
and even more disappointments. The recruit-
ment to our study was initiated at the beginning 
of pandemic in Poland, therefore, many patients 
received medications which are currently known 
to be ineffective. Chloroquine was administered to 
36% of our patients while the combined protease 
inhibitor ritonavir/lopinavir was used extremely 
rarely (2% of cases). Unfortunately, the gradually 
emerging data from controlled trials revealed 
that these drugs do not improve outcomes in this 
population [32, 33]. The available evidence shows 
a benefit associated with the administration of 
systemic glucocorticoids among patients requiring 
oxygen therapy. The use of remdesivir is currently 
suggested in patients with severe COVID-19 who 
are not critically ill. Despite initial positive signals 
from observational studies, the use of convalescent 
plasma proved to be ineffective. Routine use of 
IL-6 pathway inhibitors (tocilizumab, sarilumab) 
is not recommended, although these drugs given 
in the intensive care settings may benefit a selected 
group of critically ill patients [34].
The mortality rate in our cohort was 10% com-
pared to estimated mortality rate of 2.8% among 
the entire population of Polish COVID-19 pa-
tients [35]. The estimated mortality rate among 
hospitalized patients accounts for 18.9% and 
varies greatly depending on a study, ranging 
from 0.7 to 61.5% [36]. Such variability in the 
death rate is probably secondary to inter-country 
differences in population characteristics, health-
care-related factors as well as strategy concerning 
hospital admissions or outpatient treatment of 
COVID-19 patients.
Almost half the patients in this study were 
classified as severe cases based on the develop-
ment of respiratory failure. Univariable analysis 
comparing severe and non-severe cases showed 
that patients with severe COVID-19 more com-
monly presented with dyspnea and increased 
baseline respiratory rate as well as higher MEWS 
on admission, thus suggesting a potential clinical 
utility of the latter as a risk stratification tool 
in this population [37]. Analysis of laboratory 
results revealed that severely ill patients had 
indicators of coagulopathy, hyperinflammatory 
state, liver damage and increased cardiac bio-
markers [1, 16, 38].
Finding risk factors of severe COVID-19 is 
particularly relevant for clinician involved in 
management of COVID-19 patients. There are 
several papers reporting factors potentially asso-
ciated with mortality of severe course of the dis-
ease, however, none of them is based on a Polish 
cohort [17, 39]. In a study of 5,279 people with 
COVID-19 in New York City by Petrilli et al. [17], 
among hospitalized patients, factors associated 
with critical illness were: age, heart failure, BMI 
(greater than 40) and male sex, with diabetes be-
ing also significant. On the other hand, in a large 
Chinese study, a multivariable logistic regression 
model showed 10 potential predictors of critical 
illness. These variables included chest X-ray 
abnormalities, age, hemoptysis, dyspnea, uncon-
sciousness, the number of comorbidities, cancer 
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history, neutrophil-to-lymphocyte ratio, as well as 
concentrations of LDH and direct bilirubin [39]. 
A multivariable analysis in our study revealed 
rather similar results and suggested the increasing 
age, BMI, MEWS on admission, the highest d-di-
mer level during hospitalization and LDH concen-
tration as factors potentially related to a severe 
course of COVID-19. Unfortunately, a relatively 
small study sample reduces the statistical power 
of this analysis while single-center character of 
this study may limit its generalizability. 
There is very limited data concerning the 
clinical characteristics and outcomes of Pol-
ish patients hospitalized due to COVID-19. In 
a retrospective study by Nowak et al. [40], the 
authors reported similar distribution of signs 
and symptoms as well as comorbidities in their 
sample. Interestingly, the mortality in our cohort 
was more than two times lower despite a simi-
lar proportion of critically ill patients requiring 
a transfer to the ICU. This may be partially due 
to differences in treatment, i.e. our cohort was 
characterized by more common administration 
of currently recommended LMWH as well as less 
frequent use of chloroquine and ritonavir/lopina-
vir, both of which proved to be ineffective in the 
treatment of COVID-19. An univariable analysis 
performed in the aforementioned study suggested 
age, shortness of breath, cardiovascular disease, 
malignancy and bilateral patchy shadowing in 
chest X-ray as potential predictors of mortality in 
this population, which partially corroborates our 
results. It is however important to note that data 
presented in our study was gathered in a prospec-
tive manner, and therefore, offers more valuable 
insight into the clinical profile of Polish patients 
hospitalized due to COVID-19.
This study has several limitations. First, due 
to the limited study sample and a relatively low 
incidence of several outcomes of interest, such 
as mortality, AKI and pulmonary embolism, we 
were unable to perform multivariable analysis to 
assess risk factors for these events. Second, this 
study was performed in a single ward specialized 
in treating patients with respiratory failure, there-
fore, the presented cohort may consist of patients 
with more severe form of COVID-19 compared 
to other wards, thus limiting the generalizability 
of the results. Third, the incidence of several 
outcomes might be underestimated due to lack 
of routine screening, i.e. lack of active troponin 
level monitoring for myocardial injury or lack of 
routine deep vein ultrasound and CT pulmonary 
angiogram for venous thromboembolism. Finally, 
we believe that this cohort of first one hundred 
patients with COVID-19 treated in our center 
comprises a relatively large proportion of mild 
cases compared to later stages of the pandemic. 
Conclusion
In this observational study describing the 
clinical profile of 100 hospitalized patients with 
COVID-19, nearly half of the analyzed cases de-
veloped respiratory failure and approximately 
10% died in the course of the disease. The mul-
tivariable analysis revealed increasing age, BMI, 
MEWS on admission as well as higher d-dimer 
and LDH concentration as factors associated with 
severe course of COVID-19.
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